Search Back New search Go to resultsDiseaseMain groupHematological Diseases, Non-MalignantProtocol groupAnemias, CytopeniasDiseaseIron DeficiencySubgroupICD10D50.-E61.1MeSHAnemia, Iron-DeficiencyIron DeficienciesSequenceChemotherapyChemo-substanceChemo-substanceChemo-substanceChemo-substanceNo. Substances RadiotherapySupportive therapySupportive substanceFerric carboxymaltoseFerric DerisomaltoseSupportive substanceFerric carboxymaltoseFerric DerisomaltoseSupportive substanceFerric carboxymaltoseFerric DerisomaltoseSupportive substanceFerric carboxymaltoseFerric DerisomaltoseNo. Substances1Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationTherapy phaseTherapy intentionsupportiveRisksAllergic ReactionHypophosphatemiaRash only studiesPublicationAuthorAdkinson NAuerbach MHedenus MDiseaseEisenmangel- / Anämie, Hb ≤11 g/dL, Transferrinsättigung (TSAT) <20%, and S-Ferritin <100 ng/mLEisenmangelanämie Hämoglobin <12,0 g/dL (Frauen) und <14,0 g/dL (Männer) und Transferrinsättigung 20% oder Ferritin 100 ng/mL innerhalb von 60 Tagen nach der Verabreichung)Lymphatische Neoplasien und Anämie, Hb 8,5-10,5 g/dl, TSAT < 20%, Serum-Ferritin > 30 ng/ml, ECOG 0-2OriginDepartment of Internal Medicine, Sundsvall Hospital, Sundsvall, SwedenDepartment of Medicine, Georgetown University School of Medicine, Washington, DC, FERWON-IDA trialJohns Hopkins University School of Medicine, Baltimore, MarylandProtocols in Revision 3 protocols foundProtocols under revision.Ferric carboxymaltose 1000, Iron Deficiency/Anemia (PID905 V1.0)Ferric Carboxymaltose 750, Iron Deficiency/Anemia (PID2561 V1.0)Iron(III)-derisomaltose 1000, Iron Deficiency/Anemia (PID2449 V1.0)
